Jan 2019 $7 M No. 11 $2 to $10 million 4
Exagen Diagnostics Inc.: Raise no. 11, Jan 2019 × Investors in this round 4 investors had bought by the notice of Feb 1, 2019: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $16 M offered; $9 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Fortunato R. Rocca · Executive Officer, Director Kamal L.L. Adawi · Executive Officer Thierry L.L. Dervieux · Executive Officer Arthur L.L. Weinstein · Director Brian R. Birk · Director Daniel C. Burrell · Director Ebetuel R. Pallares · Director James L.L. Tullis · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kamal Adawi, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 1, 2019. Read the notice at the SEC .
equity SEC May 2017 $4 M No. 10 $2 to $10 million 4
Exagen Diagnostics Inc.: Raise no. 10, May 2017 × Investors in this round 4 investors had bought by the notice of May 18, 2017: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $13 M offered; $9 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Fortunato R. Rocca · Executive Officer, Director Mark L.L. Hazeltine · Executive Officer Thierry L.L. Dervieux · Executive Officer Arthur L.L. Weinstein · Director Brian R. Birk · Director Ebetuel R. Pallares · Director Frank M. Witney · Director James L.L. Tullis · Director John M. Radak · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark Hazeltine, Interim Chief Financial Officer. Source: SEC Form D, newest notice filed May 18, 2017. Read the notice at the SEC .
equity SEC Jan 2016 $17 M No. 9 $10 to $50 million 13
Exagen Diagnostics Inc.: Raise no. 9, Jan 2016 × Investors in this round 13 investors had bought by the notice of Jan 26, 2016: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $17 M of $31 M offered; $14 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Fortunato R. Rocca · Executive Officer, Director Thierry L.L. Dervieux · Executive Officer Wendy R. Swedick · Executive Officer Arthur L.L. Weinstein · Director Brian R. Birk · Director Ebetuel R. Pallares · Director Frank M. Witney · Director James L.L. Tullis · Director John M. Radak · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 26, 2016. Read the notice at the SEC .
equity SEC Oct 2015 $3 M No. 8 $2 to $10 million 4
Exagen Diagnostics Inc.: Raise no. 8, Oct 2015 × Investors in this round 4 investors had bought by the notice of Oct 21, 2015: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $5 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Fortunato R. Rocca · Executive Officer, Director Thierry L.L. Dervieux · Executive Officer Wendy R. Swedick · Executive Officer Arthur L.L. Weinstein · Director Brian R. Birk · Director Ebetuel R. Pallares · Director Frank M. Witney · Director James L.L. Tullis · Director John M. Radak · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 21, 2015. Read the notice at the SEC .
debt, options SEC Oct 2013 $5 M No. 7 $2 to $10 million 11
Exagen Diagnostics Inc.: Raise no. 7, Oct 2013 × Investors in this round 11 investors had bought by the notice of Oct 15, 2013: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions none
Finders' fees none
Paid to its own people $900,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Fortunato R. Rocca · Executive Officer, Director Thierry R. Dervieux · Executive Officer Wendy R. Swedick · Executive Officer Beto R. Pallares · Director Brian R. Birk · Director Curt R. LaBelle · Director Michael R. Walsh · Director Sam R. Riccitelli · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 15, 2013. Read the notice at the SEC .
equity SEC Sep 2012 $5 M No. 6 $2 to $10 million 7
Exagen Diagnostics Inc.: Raise no. 6, Sep 2012 × Investors in this round 7 investors had bought by the notice of Sep 11, 2012: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people $530,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Fortunato R. Rocca · Executive Officer, Director Thierry R. Dervieux · Executive Officer Wendy R. Swedick · Executive Officer Brian R. Birk · Director Curt J. LaBelle · Director David R. Blivin · Director Michael J. Walsh · Director Sam R. Riccitelli · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 11, 2012. Read the notice at the SEC .
equity SEC Dec 2011 $12 M No. 5 $10 to $50 million 9
Exagen Diagnostics Inc.: Raise no. 5, Dec 2011 × Investors in this round 9 investors had bought by the notice of Dec 22, 2011: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $12 M of $25 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people $1,600,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Fortunato R. Rocca · Executive Officer, Director Thierry R. Dervieux · Executive Officer Wendy R. Swedick · Executive Officer Brian R. Birk · Director Curtis J. LaBelle · Director David R. Blivin · Director Dinesh R. Patel · Director Michael J. Walsh · Director Sam R. Riccitelli · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 22, 2011. Read the notice at the SEC .
equity SEC Sep 2011 $5 M No. 4 $2 to $10 million 8
Exagen Diagnostics Inc.: Raise no. 4, Sep 2011 × Investors in this round 8 investors had bought by the notice of Sep 27, 2011: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $6 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people $350,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Scott L. Glenn · Executive Officer, Director Thierry J. Dervieux · Executive Officer Wendy J. Swedick · Executive Officer Brian L. Birk · Director Curtis J. LaBelle · Director David J. Bilvin · Director Dinesh L. Patel · Director Michael J. Walsh · Director Stephanie L. Spong · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 27, 2011. Read the notice at the SEC .
equity, debt SEC Jun 2011 $5 M No. 3 $2 to $10 million 8
Exagen Diagnostics Inc.: Raise no. 3, Jun 2011 × Investors in this round 8 investors had bought by the notice of Jun 29, 2011: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $6 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people $460,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Scott L. Glenn · Executive Officer, Director Thierry J. Dervieux · Executive Officer Wendy L. Swedick · Executive Officer Brian L. Birk · Director Curtis J. LaBelle · Director David J. Blivin · Director Dinesh L. Patel · Director Michael J. Walsh · Director Stephanie L. Spong · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 29, 2011. Read the notice at the SEC .
equity, options SEC Oct 2010 $5 M No. 2 $2 to $10 million 17
Exagen Diagnostics Inc.: Raise no. 2, Oct 2010 × Investors in this round 17 investors had bought by the notice of May 11, 2011: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people $550,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Scott L. Glenn · Executive Officer, Director Wendy L. Swedick · Executive Officer Brian L. Birk · Director Dinesh L. Patel · Director Michael J. Walsh · Director Stephanie L. Spong · Director Waneta C. Tuttle · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Wendy Swedick, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed May 11, 2011. Read the notice at the SEC .
equity, debt, options SEC May 2009 $1 M No. 1 Under $2 million 15
Exagen Diagnostics Inc.: Raise no. 1, May 2009 × Investors in this round 15 investors had bought by the notice of May 26, 2009: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Exagen Diagnostics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $2 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people $340,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in De People named in the notice John P. Alsobrook, II · Executive Officer Lisa Davis · Executive Officer Brian Birk · Director Dinesh Patel · Director John Bessone · Director Todd Stevens · Director Waneta C. Tuttle · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John P. Alsobrook, II, President and CEO. Source: SEC Form D, newest notice filed May 26, 2009. Read the notice at the SEC .
equity, options SEC